As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Patients with Non-Rhabdomyosarcoma Soft Tissue Sarcomas
To identify the dose of pazopanib that is feasible when given in combination with radiation or chemo-radiation in pediatric and adult patients with unresected intermediate- and high-risk NRSTS.
In order to participate you must meet the following criteria:
- Are older than 2 years of age at the time of the biopsy that established the diagnosis of NRSTS.
Have been newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk. Patients will be eligible for the chemotherapy or non-chemotherapy cohort based on:
- Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials.
- Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade.
This is a partial list of elgibility requirements.